Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
Sarepta Therapeutics (NASDAQ: SRPT) will announce its third quarter 2022 financial results on November 2, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sarepta Therapeutics (NASDAQ: SRPT) will announce its third quarter 2022 financial results on November 2, 2022, after market close. A conference call will follow at 4:30 p.m. E.T. to discuss the results. Sarepta, a leader in precision genetic medicine, focuses on rare diseases, particularly Duchenne muscular dystrophy and limb-girdle muscular dystrophies, with over 40 programs in development. The event will be available via live webcast and archived on the company's investor relations website for one year.
Positive
- Sarepta has more than 40 programs in various stages of development.
- The company holds leadership positions in DMD and LGMDs.
Negative
- None.
Details
News Market Reaction – SRPT
The recorded move for SRPT in the trading session of this news was +1.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, November 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2022 financial results.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.